Should Cubist make a bid for Optimer, I would expect it to be $16. I'm basing that on analyst Eun K. Yang's projections. His numbers on OPTR have been right on target for which he gets a "10" from Yahoo and the list of analysts that they use. Mr. Yang is with Jefferies. Does Cubist have the money to go higher?
<<10/10/12: Jefferies cut its price target on Optimer to $16.00 (from $17.00) to reflect revised U.S. sales and EU royalties.>>
I held Genentech when they got bought out. The first offer brought "experts" out to proclaim a higher offer would be revealed. That was the best time to sell, and I did. So, $19?
It's all speculation, so not to worry.